Mergers and Acquisitions

* On October 11, 2013, Hybrigenics, a bio-pharmaceutical company listed on with a focus on research and development of new treatments of proliferative diseases and specialised in protein interactions, has announced the acquisition of the genomic activities of Imaxio. To finance the future growth of the genomic services, Hybrigenics has received € 1.3 million through a private placement from Pradeyrol Development (PRD), a family office and majority shareholder of Imaxio.

 

Based in the Clermont-Limagne Biopole, near Clermont-Ferrand (France), the genomics unit of Imaxio performs fee-for-service studies specialized in extracting and sequencing DNA or RNA to get information on the genome and gene expression from any living organism, in normal or pathological conditions. This information is crucial in many applications such as the diagnosis of genetic disease, the profiling of cancers to choose the right treatment, the direct identification of bacterial or viral strains, or the characterization of improved plant cultivars. More specifically, the genomics division of Imaxio is one of the few European service providers certified by Agilent to perform its SureSelect® target enrichment, comparative genomic hybridization (CGH) and microRNA microarrays technologies. It also operates an Illumina® next generation sequencing and genotyping platform.

With the acquisition of the genomics unit of Imaxio, Hybrigenics is entering this fast-growing market, with the same high-quality fully-integrated customer-oriented policy, which is already the hallmark of Hybrigenics Services’ proteomics activities.